Ubix Therapeutics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 41

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $18.1M

  • Investors
  • 28

Ubix Therapeutics General Information

Description

Developer of protein degradation therapeutics designed to provide anti-cancer treatment. The company utilizes inhibitor technology that leverages the body's own natural protein degradation machinery to eliminate diseased proteins, thereby leading to near-complete inactivation of disease-causing pathways, enabling healthcare professionals to increase life span and improve quality of life for affected patients.

Contact Information

Website
www.ubixtrx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Suite 1401, 7, Beobwon-ro 11-gil
  • Songpa-gu
  • Seoul, 05836
  • South Korea
+82
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Suite 1401, 7, Beobwon-ro 11-gil
  • Songpa-gu
  • Seoul, 05836
  • South Korea
+82

Ubix Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ubix Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 22-Dec-2024 $18.1M Completed Clinical Trials - Phase 1
7. Accelerator/Incubator 08-Oct-2024 Completed Clinical Trials - Phase 1
6. Accelerator/Incubator 09-Nov-2023 Completed Pre-Clinical Trials
5. Later Stage VC (Series C) 27-Mar-2023 Completed Pre-Clinical Trials
4. Early Stage VC (Series B) 05-May-2020 Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 21-Feb-2019 Completed Pre-Clinical Trials
2. Seed Round 30-Nov-2018 $3.55M $3.55M Completed Pre-Clinical Trials
1. Accelerator/Incubator Completed Pre-Clinical Trials
To view Ubix Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Ubix Therapeutics Patents

  • 43

    Total Documents Applications and Grants

  • Total Patents Families

  • 6

    Granted

  • 27

    Pending

  • Expiring in next 12 mo

Ubix Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025222579-A1 Compounds with shp2 proteolytic activity and medical uses thereof Pending 14-Feb-2024
WO-2025174220-A1 Compounds with shp2 proteolytic activity and medical uses thereof Pending 14-Feb-2024
JP-2026530484-A Androgen receptor degrading compounds and their pharmaceutical uses Pending 01-Sep-2023
EP-4772505-A1 Compound for degrading androgen receptor and medical use thereof Pending 01-Sep-2023
WO-2025048557-A1 Compound for degrading androgen receptor and medical use thereof Inactive 01-Sep-2023 C07D401/14
To view Ubix Therapeutics’s complete patent history, request access »

Ubix Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ubix Therapeutics Investors (28)

Investor Name Investor Type Holding Investor Since Participating Rounds
Industrial Bank of Korea PE/Buyout Minority
KB Investment Venture Capital Minority
Korea Technology Finance Government Minority
Mint Venture Partners Accelerator/Incubator Minority
QUAD Investment Management Hedge Fund Minority
You’re viewing 5 of 28 investors. Get the full list »

Ready to get started?

Request a free trial

Ubix Therapeutics FAQs

  • When was Ubix Therapeutics founded?

    Ubix Therapeutics was founded in 2018.

  • Where is Ubix Therapeutics headquartered?

    Ubix Therapeutics is headquartered in Seoul, South Korea.

  • What is the size of Ubix Therapeutics?

    Ubix Therapeutics has 41 total employees.

  • What industry is Ubix Therapeutics in?

    Ubix Therapeutics’s primary industry is Biotechnology.

  • Is Ubix Therapeutics a private or public company?

    Ubix Therapeutics is a Private company.

  • What is Ubix Therapeutics’s current revenue?

    The current revenue for Ubix Therapeutics is .

  • How much funding has Ubix Therapeutics raised over time?

    Ubix Therapeutics has raised $48M.

  • Who are Ubix Therapeutics’s investors?

    Industrial Bank of Korea, KB Investment, Korea Technology Finance, Mint Venture Partners, and QUAD Investment Management are 5 of 28 investors who have invested in Ubix Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process